Last reviewed 2026-04-23 · How we verify

CXA-101

CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition.

CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition. Used for Complicated urinary tract infections, Complicated intra-abdominal infections.

At a glance

Mechanism of action

CXA-101 works by binding to the ferric uptake regulator (Fur) protein, thereby inhibiting the bacterial uptake of iron. This leads to a decrease in bacterial growth and proliferation. CXA-101 has shown efficacy against various Gram-negative bacteria.

Approved indications

• Complicated urinary tract infections
• Complicated intra-abdominal infections

Common side effects

• Nausea
• Vomiting
• Diarrhea

Key clinical trials

• Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation (PHASE4)
• Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) (PHASE1)
• Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
• Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens (PHASE4)
• Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia (PHASE3)
• Nosocomial Infections in ECMO Patients
• Use of New Antibiotics in Sweden
• Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.